SCHEMBL1040762

SCHEMBL1040762

O=C(O)c1ccncc1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.62
SRD5A2 P31213 2/20 0.52
KDM4C Q9H3R0 4/20 0.49
KDM5A P29375 1/20 0.49
KDM5B Q9UGL1 1/20 0.49
KMT2A Q03164 3/20 0.47
KDM4D Q6B0I6 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
KDM6B O15054 1/20 0.47
KDM4A O75164 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7824045 0.84 AKR1C3 (0.62) NR4A1KDM4CKMT2AKDM4DKDM4E
SCHEMBL7843027 0.83 LTA4H (0.58) NR4A1KDM4CKMT2AKDM4DKDM4E
SCHEMBL1921967 0.83 ROCK2 (0.50) NR4A1SRD5A2KMT2AKDM4EMEN1
SCHEMBL7804698 0.78 TGFBR1 (0.47) KDM4CKDM5AKDM5BKMT2AKDM4D
SCHEMBL71335 0.78 KDM4C (0.65) KDM4CKMT2AKDM4DKDM4EMEN1
SCHEMBL29416303 0.78 KDM4C (0.65) KDM4CKMT2AKDM4DKDM4EMEN1
SCHEMBL7850570 0.77 AKR1C3 (0.62) NR4A1KDM4CKMT2AKDM4DKDM4E
SCHEMBL30884880 0.77 NR4A1 (1.00) NR4A1SRD5A2KDM4EALDH1A1L3MBTL1
SCHEMBL1247787 0.77 NR4A1 (1.00) NR4A1SRD5A2KDM4EALDH1A1L3MBTL1
SCHEMBL7855298 0.77 LTA4H (0.58) NR4A1KDM4CKMT2AKDM4DKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051689-A1 Polycyclic Agents for the Treatment of Respiratory Syncytial Virus Infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2014-02-20 US disclosed
US-8598193-B2 Polycyclic agents for the treatment of respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) 2013-12-03 US disclosed
CN-101723949-B Polycyclic agents for treatment of respiratory syncytial virus infections BIOTA SCIENT MAN 2013-10-23 CN disclosed
EP-2287167-A1 Polycyclic agents for the treatment of respiratory syncytial virus infections BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) 2011-02-23 EP disclosed
EP-1697377-B1 POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENT MANAGEMENT (AU) 2011-01-26 EP disclosed
EP-1697377-A4 POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENT MANAGEMENT (AU) 2008-03-19 EP disclosed
US-20070287700-A1 Polycyclic agents for the treatment of respiratory syncytial virus infections BIOTA SCIENTFIC MANAGEMENMT PTY LTD. (AU) 2007-12-13 US disclosed
EP-1697377-A1 POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY. LTD. (AU) 2006-09-06 EP disclosed
WO-2005061513-A1 POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051689-A1 Polycyclic Agents for the Treatment of Respiratory Syncytial Virus Infections SDHA, SDHB, NDUFB7 NR4A1 321/4885SRD5A2 1196/4885KDM4C 2064/4885
US-20070287700-A1 Polycyclic agents for the treatment of respiratory syncytial virus infections PAICS, SDHB, SDHA NR4A1 242/4885SRD5A2 1499/4885KDM4C 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.